

Parathyroid Diseases



DR. ALI JAD ABDELWAHAB

Embryology and Surgical Anatomy




- Four parathyroid glands develop from the 3rd and 4th pharyngeal pouches between the 5th and 12 weeks of gestation
- Yellow brown in color
- Wt. 30 mg
- 5% supernumerary




- The blood supply of both the superior and inferior parathyroid glands arises from the **inferior thyroid artery**
- The inferior parathyroid gland and the thymus arise from the third pharyngeal pouch: More variation in position
- The superior parathyroid glands arise from the dorsal portion of the fourth pharyngeal pouch.

Relation to RLN




- 80% of patients
- S. parathyroid glands are at the posterior aspect of the thyroid lobe in an area 2 cm in diameter, centered 1 cm around the junction of the inferior thyroid artery and the recurrent laryngeal nerve in strict proximity to the cricothyroid junction

Localization Studies




**Nuclear medicine-
based studies
(sestamibi scanning)**



Ultrasonography



4D-CT



MRI



**Parathyroid
angiography and
venous sampling for
PTH**

Hypercalcemia



**CALCIUM IS THE MOST ABUNDANT CATION IN
HUMAN BEINGS**

Total serum calcium
8.5 to 10.5 mg/dL (2.1 to
2.6 mmol/L)

Tightly regulated.

**Normal
serum
Calcium**

**Ionized calcium 4.4 to
5.2 mg/dL (1.1 to 1.3
mmol/L).**

**Must always be
considered in its
relationship to plasma
protein levels, especially
serum albumin**

D.Dx of Hypercalcemia

- **Primary hyperparathyroidism**
- **Tertiary hyperparathyroidism**
- **Familial hypercalcemic hypocalciuria**
- **Lithium therapy**
- **Paraneoplastic syndrome (humoral hypercalcemia of malignancy)**
- **Osteolytic metastases**
- **Multiple myeloma**
- **Drug-induced hypercalcemia**
- **Granulomatous disease**
- **Hypervitaminosis D**
- **Milk-alkali syndrome**
- **Nonparathyroid endocrine disease**
- **Immobilization**
- **Idiopathic**

Primary Hyperparathyroidism (PHPT)



- **Occurs in 0.1% to 0.3% of the general population**
- **More common in women (1:500) than in men (1:2000).**

Disease Mechanisms

Increased PTH production  Hypercalcemia via:

- Increased GI absorption of calcium
- Increased production of vitamin D₃
- Reduced renal calcium clearance

Primary Hyperparathyroidism



- **PTH is elevated relative to the serum calcium level.**
- **Serum phosphate is often low**
- **Renal function is normal**

Causes

- **Parathyroid adenoma (85%)**
- **Parathyroid hyperplasia (15%)**
- **Parathyroid carcinoma (<1%).**

Clinical Picture



Classical mnemonic :“stones, bones, groans, moans, and psych overtones,”

Stones

Urolithiasis

bones

Bone diseases including bone resorption with cyst (osteitis cystica) and brown tumor formation

groans

Abdominal pain from peptic ulcers or pancreatitis

moans

Diffuse joint and muscle pains, fatigue and lethargy

psych overtones

Neuropsychiatric abnormalities including depression or worsening psychosis

Currently most patients are found incidentally from investigating hypercalcemia



In outpatients

- **The most common cause of hypercalcemia is primary hyperparathyroidism**

In inpatients

- **The most common cause is malignancy, either via paraneoplastic syndrome or bony metastases**

Treatment



Medical

- **Acute, severe hypercalcemia : large-volume saline infusion**
- **There is no definitive medical treatment for primary or tertiary hyperparathyroidism**

Surgical

- **Patient selection criteria for parathyroidectomy include asymptomatic patients <50 years of age**

NIH Criteria for Parathyroidectomy



Age < 50 OR Any age with any of the following:

Nephrolithiasis

Osteitis fibrosa cystica

Serum calcium >1.0 mg/dL above reference range (typically >11.2)

Hypercalciuria (>400 mg/day)

Bone mineral density T score reduced by >2.5 SD measured at one or more sites

Creatinine clearance reduced by 30% compared to age-matched normal range

History of an episode of life-threatening hypercalcemia

Neuromuscular symptoms: documented proximal weakness, atrophy, hyperreflexia, and gait disturbance

Observation Vs. Operation



Observation rather than operation is not safe for noncompliant patients.

Observation requires active surveillance :

biannual serum calcium levels

annual serum creatinine measurement


annual bone mineral density determination

Secondary Hyperparathyroidism

Causes

- **Chronic renal failure**
- **Inadequate calcium intake**
- **Decreased vitamin D**
- **Malabsorption**

Pathophysiology



Secondary Hyperparathyroidism



Clinical Picture

- **Bone pain,**
- **Soft tissue calcifications (calcinosis)**
- **Pruritus**

Lab. Results

- **Increased PTH**
- **Normal calcium**
- **Raised phosphate**

Treatment




Medical

- **For end-stage renal disease**
 - ❑ **Dialysis**
 - ❑ **Vitamin D supplements**
 - ❑ **Oral phosphate binders**
- **Cinacalcet (Sensipar): lowers calcium by activating the calcium-sensing receptor**

Surgical

- **For end-stage renal disease: transplantation**
- **Parathyroidectomy for**
 - ❑ **Ongoing bone loss**
 - ❑ **Soft tissue calcifications**
 - ❑ **Severe pruritus**
 - ❑ **Patients on lithium who develop hypercalcemia and cannot be managed with other medications**

- **Since secondary hyperparathyroidism is always multiglandular, at least subtotal parathyroidectomy (three and one-half gland) should be performed**



Tertiary Hyperparathyroidism



Definition

- **One or more of the hyperplastic glands of a patient with secondary hyperparathyroidism becomes an autonomous producer of PTH**

Suspicion

- **PTH levels remain high despite successful renal transplantation in most cases**
- **Patients who remain on dialysis and spontaneously progress from secondary to tertiary hyperparathyroidism marked by the onset of hypercalcemia.**



Elevated intact PTH plus Hypercalcemia

Primary and tertiary hyperparathyroidism

Familial hypercalcemic hypocalciuria (FHH, also called familial benign hypercalcemia),

Vitamin D deficiency

Lithium induced hypercalcemia

PTHrP



Serum parathyroid hormone–related peptide (PTHrP) level might be useful when occult malignancy is a concern:

-Bronchial squamous cell carcinoma is the commonest. – Other sources: breast, renal, and ovarian

Bone destruction by primary cancers (e.g., multiple myeloma) or lytic bony metastases causes hypercalcemia without PTHrP elevation

Vitamin D analogues are secreted by some tumors (e.g., lymphoma) and can produce hypercalcemia without PTH or PTHrP elevations

Surgery for Tertiary Hyperparathyroidism

- **Guided by the intraoperative findings, most often multiglandular disease.**

- **Total parathyroidectomy with forearm autotransplant or subtotal parathyroidectomy**

MULTIPLE ENDOCRINE NEOPLASIA SYNDROMES



- **Familial endocrine tumor syndromes**
- **Inherited as autosomal dominant**
- **Divided into three types**

MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN-1)



Glands and Sites Involved

Type of Disease

Parathyroid

Hyperplasia

Pancreas

Islet cell tumors

Pituitary

Adenoma

Adrenal

Adenoma or carcinoma

Enterochromaffin system

Carcinoid tumor

Soft tissue

**Lipoma
Facial angiofibroma
Collagenoma**


Screening




Should begin during the 2nd or 3rd decade

Screening tests include

Calcium, prolactin, fasting glucose and insulin, gastrin



Calcium and PTH levels should be measured in all patients



The absence of hyperparathyroidism virtually excludes MEN-1

Parathyroid Disease in MEN-1

Primary hyperparathyroidism is the most common endocrine disorder in MEN-1

- **In over 90% of cases**
- **Only 3% of all cases of primary hyperparathyroidism.**

Mean age of onset is 25 years

- **Much younger than for sporadic primary hyperparathyroidism**
- **Affects all parathyroid glands**

Patients with hypercalcemia and hypergastrinemia should undergo parathyroidectomy first for optimal control of gastrin secretion

- **Either total (four gland) parathyroidectomy with forearm autotransplant or subtotal (three and one-half gland) parathyroidectomy is appropriate**
- **The cervical thymus should always be removed because supernumerary glands can occur and are usually within the thymus**

Treatment



Therapeutic goals :controlling symptoms of hormonal excess and malignancy excision

Gastrinomas are usually multiple, malignant and resection requires pancreaticoduodenectomy

Surgery is appropriate for all insulinomas

Parathyroidectomy should precede operation for gastrinoma in hypercalcemic patients

Multiple Endocrine Neoplasia Type 2A, Type 2B, And Familial Medullary Thyroid Carcinoma



- **Medullary thyroid cancer (MTC) is the primary component for each.**

MEN-2A

- **MTC**
- **Adrenal pheochromocytoma**
- **Primary hyperparathyroidism**

MEN-2B

- **MTC**
- **Adrenal pheochromocytoma**

Familial Medullary Thyroid Carcinoma (FMTC)

- **MTC**

Screening



**Genetic screening(RET DNA analysis)
has largely replaced calcitonin screening**

Performed soon after birth and is performed once in a lifetime.

Patients at risk but with negative RET testing do not require further screening.

Positive RET results lead to thyroidectomy and further evaluation

THANK YOU

